151 related articles for article (PubMed ID: 33329760)
21. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
Miyawaki Y; Nakajima Y; Kawada K; Okada T; Tokairin Y; Kawano T
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27001629
[TBL] [Abstract][Full Text] [Related]
23. Advanced signet-ring cell carcinoma of the stomach: Clinicopathological characteristics of patients and efficacy of the modified docetaxel, cisplatin, and fluorouracil regimen.
Bozkaya Y; Erdem GU; Özdemir NY; Hocazade C; Yazici O; Demirci NS; Zengin N
J Cancer Res Ther; 2018 Sep; 14(Supplement):S742-S747. PubMed ID: 30249897
[TBL] [Abstract][Full Text] [Related]
24. Gastric adenocarcinoma with neuroendocrine differentiation: Clinicopathological features and efficacy of modified DCF chemotherapy.
Bozkaya Y; Ozdemir N; Colak A; Zengin N
J BUON; 2017; 22(4):919-925. PubMed ID: 29155521
[TBL] [Abstract][Full Text] [Related]
25. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen.
Sendur MA; Ozdemir N; Özatlı T; Yazıcı O; Aksoy S; Ekinci AS; Yazılıtaş D; Günaydın Y; Oksuzoglu B; Benekli M; Zengin N
Med Oncol; 2014 Sep; 31(9):153. PubMed ID: 25099765
[TBL] [Abstract][Full Text] [Related]
26. Comparison of health-related quality of life with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil chemotherapy regimens as first-line systemic therapy in locally advanced inoperable or metastatic gastric or gastro-esophageal junction adenocarcinoma: A prospective study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Suresh Babu MC; Rudresha AH; Lokesh KN; Rajeev LK
South Asian J Cancer; 2018; 7(1):11-15. PubMed ID: 29600225
[TBL] [Abstract][Full Text] [Related]
27. The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma.
Takeuchi M; Kawakubo H; Mayanagi S; Yoshida K; Irino T; Fukuda K; Nakamura R; Wada N; Takeuchi H; Kitagawa Y
World J Surg; 2019 Aug; 43(8):2006-2015. PubMed ID: 30972432
[TBL] [Abstract][Full Text] [Related]
28. The Comparison of mDCF and mFOLFOX-6 as First-Line Treatment in Metastatic Gastric Cancer.
Acikgoz Y; Aktürk Esen S; Ucar G; Dirikoc M; Ergun Y; Bal O; Uncu D
Cureus; 2021 May; 13(5):e14882. PubMed ID: 34104608
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus.
Yamagata Y; Saito K; Hirano K; Oya M
World J Surg Oncol; 2020 Sep; 18(1):252. PubMed ID: 32962718
[TBL] [Abstract][Full Text] [Related]
30. Outcome of FOLFOX and Modified DCF Chemotherapy Regimen in Patients with Advanced Gastric Adenocarcinoma.
Pourghasemian M; Danandeh Mehr A; Molaei M; Habibzadeh A
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2337-2341. PubMed ID: 32856863
[TBL] [Abstract][Full Text] [Related]
31. Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) as a Neoadjuvant Chemotherapy for Non-metastatic Esophageal Cancer (nMEC).
Onitilo AA; Stankowski-Drengler TJ; Shiyanbola O; Engel J; Tanimu S; Fagbemi SO; Li YH
Clin Med Res; 2021 Jun; 19(2):64-71. PubMed ID: 33789952
[No Abstract] [Full Text] [Related]
32. Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.
Turkeli M; Aldemir MN; Cayir K; Simsek M; Bilici M; Tekin SB; Yildirim N; Bilen N; Makas I
Asian Pac J Cancer Prev; 2015; 16(3):985-9. PubMed ID: 25735393
[TBL] [Abstract][Full Text] [Related]
33. Modified docetaxel, cisplatin, and 5-fluorouracil combination regimen and capecitabine maintenance in metastatic gastric cancer: toxicity and efficacy results.
Arslan C; Atilla FD
Support Care Cancer; 2022 May; 30(5):4447-4455. PubMed ID: 35106659
[TBL] [Abstract][Full Text] [Related]
34. High pathologic complete remission rate from induction docetaxel, platinum and fluorouracil (DCF) combination chemotherapy for locally advanced esophageal and junctional cancer.
Noronha V; Joshi A; Jandyal S; Jambhekar N; Prabhash K
Med Oncol; 2014 Sep; 31(9):188. PubMed ID: 25148898
[TBL] [Abstract][Full Text] [Related]
35. Squamous cell carcinoma of the anus successfully treated with multidisciplinary therapy for metachronous metastatic and local recurrences after DCF chemotherapy: a case report.
Naito R; Shiraishi T; Hosoi N; Watanabe T; Shioi I; Shibasaki Y; Nakazawa N; Osone K; Okada T; Sano A; Sakai M; Ogawa H; Sohda M; Shirabe K; Saeki H
Surg Case Rep; 2024 Mar; 10(1):71. PubMed ID: 38526705
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis.
Nishiwaki N; Noma K; Kunitomo T; Hashimoto M; Maeda N; Tanabe S; Sakurama K; Shirakawa Y; Fujiwara T
Esophagus; 2022 Oct; 19(4):626-638. PubMed ID: 35792947
[TBL] [Abstract][Full Text] [Related]
37. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Matsumura S; Iwahashi M; Yamaue H
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 26725778
[TBL] [Abstract][Full Text] [Related]
38. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
Ozdemir NY; Abali H; Oksüzoğlu B; Budakoglu B; Uncu D; Güler T; Odabaşi H; Zengin N
Med Oncol; 2010 Sep; 27(3):680-4. PubMed ID: 19633962
[TBL] [Abstract][Full Text] [Related]
39. Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis.
Chen XL; Chen XZ; Yang C; Liao YB; Li H; Wang L; Yang K; Li K; Hu JK; Zhang B; Chen ZX; Chen JP; Zhou ZG
PLoS One; 2013; 8(4):e60320. PubMed ID: 23593191
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
Shah MA; Jhawer M; Ilson DH; Lefkowitz RA; Robinson E; Capanu M; Kelsen DP
J Clin Oncol; 2011 Mar; 29(7):868-74. PubMed ID: 21189380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
